Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...

Cytokinetics (NASDAQ:CYTK – Get Free Report) was upgraded by Morgan Stanley from an “equal weight” rating to an “overweight” rating in a report issued on Thursday,Benzinga reports. The brokerage ...

Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Gilead Sciences in a report ...

SAN DIEGO, CA – Daré Bioscience, Inc., a biopharmaceutical company with a current market capitalization of $26.45 million and trading at $3.04 per share, is facing potential delisting from the Nasdaq ...

Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...

Richard Paolone is a Toronto-based securities lawyer with extensive experience in corporate finance, securities law, and mergers and acquisitions. Mr. Paolone plays a key role in advising on a range ...

Entero Therapeutics has named Richard Paolone as interim chief executive.

In conjunction with (i) the royalty financing deal with HealthCare Royalty (HCRx) announced on January 30, 2025, and (ii) the final terms of the dual proposal to the 2025 OCEANEs holders announced on ...

Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...